Colossal Biosciences says it used novel gene-editing technology to alter gray wolf DNA to breed the animals. Dire wolves ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

“But with these individuals now gone, companies fear we are entering a period of years to build back up an experienced workforce.” One biotech has already received conflicting feedback from a ...

In 2024, biotechnology companies were the second most targeted industry for securities class action litigation, according to the D&O Databox™, Woodruff Sawyer’s proprietary database of ...

The U.S.-based biotechnology company is also known for its ambitious goal of bringing back the extinct woolly mammoth by 2028. This dire wolf pup is among the first of its species born in around ...

Houston-based clinical-stage biotechnology company FibroBiologics Inc. opened a manufacturing laboratory at 9350 Kirby Drive in the Texas Technology Park. It will bring manufacturing operations in ...

This resurrection achievement is a massive step in validating that valuation ...

"We're going to put tariffs on the pharmaceutical companies, and they're going to all want to come back," Trump said, speaking from the Oval Office. The raw ingredients of almost all medications ...

Or, maybe, it's just a grey wolf with a few tweaks. American biotech company Colossal Biosciences made a surprise announcement Monday, claiming it had brought the dire wolf back from the dead ...

The U.S.-based biotechnology company is also known for its ambitious goal of bringing back the extinct woolly mammoth by 2028. The full story of the dire wolves' return airs on Tuesday ...

If these times have anything to say about it, the next Microsoft is coming from the biotech sector. Investors are moving in looking for profits, even putting companies without products on the map.